SHERIDAN, WYOMING - April 14, 2026 - NS Pharma, Inc., a U.S.-based biopharmaceutical subsidiary of Japan's Nippon Shinyaku Co., Ltd., presented 4.5-year clinical trial data for brogidirsen (NS-089/NCNP-02) at the 2026 MDA Clinical & Scientific Conference on March 6, 2026, representing the most extensive longitudinal dataset disclosed to date for this Duchenne muscular dystrophy exon-skipping candidate. The presentation followed a 3.5-year data readout at the 2025 World Muscle Society Congress in October 2025, reflecting a deliberate, incremental evidence-building strategy for the compound. Concurrently, the company's JAK1 inhibitor NS-229 has entered a global Phase 2 trial for eosinophilic granulomatosis with polyangiitis (EGPA), extending NS Pharma's clinical footprint beyond neurology into rare inflammatory disease.
Business Impact
The compression of two major data presentations - 3.5-year and 4.5-year - into a five-month window signals an accelerating evidence trajectory for brogidirsen at a stage where long-term functional outcomes are increasingly decisive for regulatory review and payer coverage decisions in rare disease. In September 2025, the FDA separately granted Orphan Drug Designation to NS-051/NCNP-04, a second DMD candidate, providing NS Pharma with a seven-year market exclusivity window upon potential approval, eligibility for accelerated review pathways, and qualifying clinical trial tax credits. For Nippon Shinyaku, these compounding milestones incrementally de-risk a rare disease portfolio that already includes Viltepso, a commercialized exon-skipping product and registered trademark of the parent company. The dual-indication strategy also broadens the addressable patient population across two unrelated rare disease markets.
Clinical Development and Pipeline
Brogidirsen targets patients whose DMD mutations are amenable to exon 44 skipping within the dystrophin gene, which contains 79 exons. The therapeutic objective is to enable production of a truncated but functional dystrophin protein, slowing disease progression in a genetically defined patient subset. Viltepso's commercial precedent provides a de-risked regulatory template for subsequent exon-skipping candidates, including NS-051/NCNP-04, which now carries Orphan Drug status. The parallel development of NS-229 for EGPA - a rare autoimmune condition characterized by overactive eosinophils, asthma, rashes, and nerve pain - diversifies NS Pharma's clinical exposure into selective JAK1 inhibition, a mechanistically distinct modality from its exon-skipping work.
Operational and Sector Context
Rare disease drug development requires sustained investment in regulatory strategy, clinical operations, and patient community engagement, all of which NS Pharma is actively resourcing. A recent addition to the Clinical Research team, with a background spanning regulatory compliance, trial management, and experience at organizations including Neumora and Regeneron, indicates that clinical operations capacity is being scaled in line with the broadening pipeline. NS Pharma's involvement in patient community events, including Cure Duchenne gatherings and the 2026 Brian McKenna TetraSki Express National Championship, reflects a sector norm in rare disease where community trust and patient recruitment are operationally linked. The company's scientific approach now encompasses exon-skipping, cell therapy, and JAK1 inhibition, positioning it across three distinct rare disease therapeutic technologies.
**Key facts:**
- Brogidirsen (NS-089/NCNP-02) 4.5-year DMD trial data presented at the 2026 MDA Clinical & Scientific Conference, March 6, 2026
- 3.5-year brogidirsen data presented at the 2025 World Muscle Society Congress, October 14, 2025
- FDA granted Orphan Drug Designation to NS-051/NCNP-04 for Duchenne muscular dystrophy, September 19, 2025
- NS-229 (selective JAK1 inhibitor) entered a global Phase 2 trial for EGPA
- NS Pharma is a U.S. subsidiary of Nippon Shinyaku Co., Ltd., Japan; Viltepso is a commercially approved product of the parent